1. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy
- Author
-
Giannakopoulos, B, Krilis, S, de Jesus, G, Levy, R, Rosa, R, Andrade, D, Fortin, Pf, Zhang, Z, Zuily, S, Wahl, D, Tektonidou, M, Nalli, C, Andreoli, L, Tincani, A, Chighizola, Cb, Gerosa, M, Meroni, P, Banzato, A, Pengo, V, Sciascia, S, De Ceulaer, K, Davis, S, Atsumi, T, Uthman, I, Derksen, R, Degroot, P, Ugarte, A, Ruiz Irastorza, G, Rodriguez-Pinto, I, Pons-Estel, G, Cervera, R, Rodriguez, E, Aguirre Zamorano MA, Lopez-Pedrera), R, Mackie, I, Efthymiou, M, Cohen, H, Bertolaccini, Ml, Cuadrado, M, Khamashta, M, Sanna, G, Petri, M, Roubey, R, Knight, Js, Ortel, T, Gonzalez, E, Willis, Jhon Raymond, Levine, S, Rand, J, Belmont, Hm, Barbhaiya, M, Erkan, D, Salmon, J, Lockshin, M, Branch, W, Jackson, Wg, Oromendia, C, Unlu, O, and Desancho, Mt
- Subjects
030203 arthritis & rheumatology ,medicine.medical_specialty ,biology ,medicine.drug_class ,business.industry ,Anticoagulant ,Hematology ,030204 cardiovascular system & hematology ,Single Center ,medicine.disease ,Thrombosis ,Thrombosis and Hemostasis ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,Antiphospholipid syndrome ,Internal medicine ,Antithrombotic ,medicine ,biology.protein ,In patient ,Antibody ,business - Abstract
Management for patients with antiphospholipid syndrome (APS) and arterial thrombosis is controversial. There are no prospective data demonstrating the superiority of high- or moderate-intensity anticoagulation with vitamin K antagonists over antiplatelet agents. Using 2 antiphospholipid antibody databases (single center [New York Presbyterian Hospital] and multicenter [Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking]), we retrospectively collected demographic and clinical data of patients with APS and arterial thrombosis. The primary outcome was recurrent thrombosis rate after initial arterial thrombosis in patients with APS treated with antiplatelet and/or anticoagulant therapy. We identified 139 patients with a median follow-up time of 4.24 years after initial thrombosis. Thirty-seven patients (27.3%) received anticoagulants, 43 (30.9%) antiplatelets, and 58 (41.7%) combined therapy. Sixteen patients (37.2%) in the antiplatelet group, 9 (23.7%) in the anticoagulant group, and 4 (6.9%) in the combined therapy group experienced recurrent thrombosis. We estimate that 20% of patients will experience a recurrence by 3.4, 7.3, and 16.3 years, respectively, depending on assignment to antiplatelet, anticoagulant, or combined therapy. These results suggest that combined therapy decreases the rate of and increases the time to thrombosis recurrence in patients with APS presenting with arterial thrombosis.
- Published
- 2017
- Full Text
- View/download PDF